PerkinElmer, Inc., a leading global company in the life sciences and diagnostics sectors, is headquartered in the United States. Founded in 1937, PerkinElmer has established itself as a pioneer in providing innovative solutions across various industries, including healthcare, environmental testing, and food safety. With a strong presence in North America, Europe, and Asia, the company offers a diverse range of core products and services, such as analytical instruments, reagents, and software solutions. PerkinElmer's commitment to advancing human and environmental health is reflected in its cutting-edge technologies and comprehensive support services. Recognised for its significant contributions to the field, PerkinElmer has achieved notable milestones, including advancements in genetic testing and diagnostics. This positions the company as a trusted partner in the scientific community, dedicated to improving lives through innovation.
How does Perkinelmer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Perkinelmer's score of 36 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2021, PerkinElmer reported total carbon emissions of approximately 29,928,000 kg CO2e, comprising 7,579,000 kg CO2e from Scope 1 and 22,349,000 kg CO2e from Scope 2. This marked a decrease from 2020, when their combined Scope 1 and 2 emissions were about 27,774,000 kg CO2e, and from 2019, which saw emissions of approximately 28,000,000 kg CO2e. PerkinElmer has set ambitious climate commitments, aiming for a 50.4% reduction in Scope 1 and 2 emissions by 2032, with a baseline year of 2020. Additionally, they are targeting net carbon neutrality by 2040. These targets have been raised from an earlier goal of a 30% reduction by 2030 to align with the latest guidance from the Science Based Targets Initiative (SBTi). The company has also committed to reducing absolute Scope 1 GHG emissions by 58.8% by 2034 from a 2023 base year and aims to increase its sourcing of renewable electricity from 0% in 2023 to 100% by 2030. Furthermore, PerkinElmer plans to reduce Scope 3 GHG emissions by 63.8% per USD value added by 2034, demonstrating a comprehensive approach to addressing its carbon footprint across all scopes. These initiatives reflect PerkinElmer's commitment to sustainability and its proactive stance in mitigating climate change impacts within the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 0,000,000 |
| Scope 2 | - | - | - | - | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Perkinelmer has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Perkinelmer's sustainability data and climate commitments